Close menu




June 12th, 2023 | 08:00 CEST

Disruption! From now on, everything will be different: PayPal, BYD, BioNXt

  • Biotechnology
  • Pharma
  • Electromobility
  • Software
Photo credits: pixabay.com

What is now called disruption in the startup scene has always existed. It refers to creative destruction, cutting old ties and rethinking things from the ground up. Companies that create marketable products in this way have an edge over the competition - and score points on the market with their uniqueness. We present three titles.

time to read: 3 minutes | Author: Nico Popp
ISIN: PAYPAL HDGS INC.DL-_0001 | US70450Y1038 , BYD CO. LTD H YC 1 | CNE100000296 , Bionxt Solutions Inc. | CA0909741062

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    PayPal's recipe for success: Easier, faster, cheaper

    When the payment service PayPal was founded in Palo Alto, California, in 1998, most people in Germany still dialled into the Internet via modem or ISDN. Marketplaces, such as online auction houses, only spread gradually and lived above all from their innovative power. Peter Thiel's team quickly realized that the comparatively young Internet would soon be of great commercial importance and that a payment service was needed. The following years can be summarized quickly: Since 2004, PayPal has been available in Germany, and since 2007, the Company has also had a banking licence in Europe.

    Compared to traditional financial institutions, PayPal quickly gained the upper hand on the internet - even though credit cards were initially the number one means of payment online. However, problems with security and handling drove customers to PayPal in droves. The cooperation with eBay, to which PayPal even belonged for a time, also contributed to the spread of the service. Those who regularly bought things at auction soon no longer wanted to use bank transfers and appreciated buyer protection. Today, PayPal is so strongly positioned in the market that one can trust the share despite recession worries. Despite the share price losses, PayPal is still up more than 65% over eight years.

    BYD: Flat screen instead of sports chassis

    The Chinese carmaker BYD is also something of a revolutionary. In the same period, the share even generated a return of a whopping 429% - and that despite the fact that the share is also already trading well below its all-time high. Why is that? BYD was an early adopter of electric mobility. This spring, it even stopped building internal combustion vehicles altogether. Another unique selling point of BYD is that the Company relies heavily on connectivity and technical bells and whistles. Large displays, WLAN, Bluetooth and lots of LEDs are more convincing to Chinese customers than a tight chassis. Why this is so is not surprising - after all, cars on China's roads send data to the authorities every thirty seconds. Driving pleasure is then quickly redefined. But back to BYD: As a promising company in the most important car market, the share is naturally highly rated. Whether the exit of Berkshire Hathaway or worries about a trade war between East and West: this market position is convincing and unique.

    BioNxt does it better and cheaper

    Completely free of worries about trade wars or financial crises are shareholders of the Canadian biotech BioNxt. The Company has positioned itself in various promising areas and sees itself as a problem solver within the healthcare system. The German subsidiary Vektor Pharma TF GmbH has developed a patch around the well-known Parkinson's drug rotigotine that can compete with original preparations in studies. A clinical trial of the product is currently underway, with the results expected by late summer. Only a few months ago, a court in the US cleared the way for generics in this very field. Also, a few months ago, BioNxt received an order to produce an orally soluble product. To fulfil this order, the Company has invested in a coating and cutting machine at its Biberach site.

    The business field of innovative dosage forms, which is also gaining commercial momentum, is extremely promising for BioNxt Solutions. The Company does not rule out acting as a contract manufacturer in other areas in the future. The dose can be adjusted depending on how effectively an active substance reaches the patient. This saves costs and strikes a chord with already cash-strapped healthcare systems worldwide. The incipient commercialization can be an opportunity for investors. In parallel, BioNxt is involved in the diagnostics sector, offering self-tests related to oral health. There is already a letter of intent for the production of biosensor products for testing inflammatory diseases of the oral cavity, such as those that occur as a side effect of drugs for opioid abuse, for the US market.


    Companies that have rethought tried-and-tested products from the ground up are also successful on the stock market - good examples are PayPal and BYD. BioNxt Solutions has made significant progress in the commercialization of its product range in recent months. If the positive trend continues and the figures are right, the share, which currently represents an enterprise value of around CAD 58 million, should be seen by many investors with new eyes.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Fabian Lorenz on November 1st, 2024 | 07:00 CET

    Takeover fever and buy recommendation! Evotec, Nel ASA, Barrick Gold, Desert Gold

    • Mining
    • Gold
    • Biotechnology
    • Pharma
    • renewableenergies

    A hot takeover candidate in the gold sector is Desert Gold. Gold production in West Africa is expected to start in 2025. It is quite possible that one of the major gold companies will make a move by then. After the disappointing quarterly figures from Barrick Gold and Newmont calls for takeovers are growing louder. Analysts see significant upside potential. In the biotech sector, Evotec is repeatedly being discussed as a takeover candidate. The core business is considered extremely attractive, and the new CEO is expected to eliminate all the legacy issues this year. Next week will be exciting! And then there is Nel. Operationally, things are not going well for the former hydrogen star. Can the collaboration with a potential buyer turn things around?

    Read

    Commented by André Will-Laudien on October 31st, 2024 | 07:15 CET

    Uranium Energy Rally 3.0! Another 100% with acquisitions at Nel, F3 Uranium, Plug Power, JinkoSolar and ARI Motors

    • Mining
    • Uranium
    • renewableenergies
    • Solar
    • Electromobility
    • Hydrogen

    Energy policy has become quite complex. The EU sanctions fossil fuels and gold from Russia but leaves out uranium. Why? There is one nuclear energy fan that vehemently opposes it behind the scenes in Brussels: France! Other countries like Poland, the Czech Republic, and Finland have also emerged as followers. Sweden and Romania each have two additional reactors in the planning stage, which the authorities have already approved. So, it is a two-tier society within the EU, which leaves Economic Minister Robert Habeck looking particularly foolish, especially as he secured costly LNG gas from Qatar on a 10-year contract to shut down domestic reactors. More mismanagement is hardly possible. The fact remains: with the renewed demand for uranium, supply will likely struggle to keep up in the coming years. F3 Uranium holds extensive concessions in the largest uranium mining district in the world: the Athabasca Basin. The industry is preparing for the impending supply bottleneck with acquisitions and purchases. Investors have the potential to double their returns now!

    Read

    Commented by Fabian Lorenz on October 31st, 2024 | 07:00 CET

    Siemens Energy unstoppable! BYD in a trade war? First Hydrogen share set for a price jump?

    • Hydrogen
    • greenhydrogen
    • renewableenergies
    • Electromobility
    • Energy

    More and more analysts are suggesting it might be time to sell Siemens Energy stock. After all, the share is one of the top performers this year, with a price gain of more than 200%. What are the arguments in favour of selling? In contrast, anti-cyclical investors could add First Hydrogen shares to their portfolios. With plans to roll out hydrogen solutions for commercial vehicles across Europe, First Hydrogen's stock appears to have stabilized and represents the new generation in the hydrogen sector. Meanwhile, BYD is growing strongly. The Chinese are aiming for an aggressive expansion in Europe, but what do the new punitive tariffs mean? Is a trade war looming?

    Read